Idecabtagen vicleucel (multiple myeloma. ≥ 3 previous therapies)

Subject:

• Active Substance: Idecabtagen vicleucel
• Name: Abecma^®
• Therapeutic area: Multiple myeloma
• Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

• Start: 01.01.2022
• Final decision by G-BA: 16.06.2022

Final decision:

• Hint for a non-quantifiable additional benefit